Aethlon Medical (NASDAQ:AEMD) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research report report published on Sunday. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright lowered their price target on shares of Aethlon Medical from $23.00 to $10.00 and set a buy rating for the company in a research report on Monday, March 4th.

Aethlon Medical Stock Performance

Shares of NASDAQ:AEMD opened at $1.32 on Friday. The stock has a market capitalization of $3.46 million, a price-to-earnings ratio of -0.26 and a beta of 1.88. Aethlon Medical has a 1-year low of $1.30 and a 1-year high of $5.00. The company’s fifty day moving average is $1.62 and its two-hundred day moving average is $1.75.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, February 14th. The medical equipment provider reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.14). Sell-side analysts expect that Aethlon Medical will post -4.98 EPS for the current fiscal year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.